InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research report sent to investors on Thursday. The firm issued a sell rating on the stock.

InspireMD Price Performance

Shares of NYSE:NSPR opened at $2.50 on Thursday. The stock’s 50-day moving average is $2.38 and its 200 day moving average is $2.50. The company has a market cap of $62.21 million, a PE ratio of -3.28 and a beta of 0.95. InspireMD has a 1 year low of $1.81 and a 1 year high of $3.85.

InspireMD (NYSE:NSPR) last posted its earnings results on Tuesday, May 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.06). The business had revenue of $1.51 million for the quarter, compared to analysts’ expectations of $1.38 million. InspireMD had a negative net margin of 350.35% and a negative return on equity of 55.12%. During the same period last year, the firm posted ($0.53) earnings per share. Analysts expect that InspireMD will post -0.82 EPS for the current fiscal year.

Institutional Trading of InspireMD

An institutional investor recently bought a new position in InspireMD stock. McKinley Carter Wealth Services Inc. bought a new stake in InspireMD, Inc. (NYSE:NSPR) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 10,000 shares of the company’s stock, valued at approximately $28,000. Institutional investors and hedge funds own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.